|Mr. Mark Christopher Trudeau||Pres, CEO & Director||4.61M||N/A||1961|
|Mr. Bryan M. Reasons||Exec. VP & CFO||1.73M||N/A||1967|
|Mr. Hugh M. O'Neill||Exec. VP & Chief Commercial and Operations Officer||1.91M||N/A||1963|
|Dr. Steven J. Romano||Exec. VP & Chief Scientific Officer||2.12M||N/A||1959|
|Mr. Mark J. Casey||Exec. VP & Chief Legal Officer||2.06M||N/A||1963|
|Mr. Daniel J. Speciale CPA, CPA||VP of Fin. & Investor Relations Officer||N/A||N/A||N/A|
|Ms. Michele Robertson||Sr. VP & Chief Compliance Officer||N/A||N/A||N/A|
|Ms. Brandi Robinson||Sr. VP & Chief Communications Officer||N/A||N/A||N/A|
|Mr. Ian J. Watkins||Exec. VP & Chief HR Officer||N/A||N/A||1963|
|Mark Tyndall||Sr. VP of Gov. Affairs & Chief Counsel of Litigation||N/A||N/A||N/A|
Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers Acthar Gel, an injectable drug for rheumatoid arthritis, multiple sclerosis, infantile spasms, systemic lupus erythematosus, polymyositis, and others; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; and Therakos photopheresis, an immunotherapy treatment platform, as well as Amitiza, a product for constipation. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; StrataGraft, which is in Phase III and II clinical development for the treatment of burns; MNK-6105 and MNK-6106, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; and SLN500, a ribonucleic acid technology therapy. It markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc. The company was founded in 1867 and is based in Dublin, Ireland. On October 12, 2020, Mallinckrodt plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Mallinckrodt plc’s ISS Governance QualityScore as of November 1, 2019 is 6. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 2; Compensation: 10.